CBS MARKETWATCH TOP NEWS
Hardware stocks rise; finish best week of the year
U.S. stocks end mixed in listless preholiday trade
U.S. April inflation gauge moderates
Treasurys end down on manufacturing strength
Dell execs cash in big on stock options, filing shows




Sign up for FREE e-Newsletters



The first step in the selection of the best possible topical formulation for the human clinical trials is the use of the radio labeled ENT-103 to test the efficiency of a variety of formulations designed to deliver ENT-103 across human skin. In vitro absorption studies using human skin are scheduled to begin in late June at Dow Pharmaceutical Sciences. These studies will measure both the rate and extent of ENT-103 transport across the skin.

"Radio labeling or tagging allows us to test various formulations to evaluate the amount of ENT-103 that is absorbed. The preparation of radio labeled ENT-103 is an important step in the determination of the optimal topical formulation for use in our upcoming human clinical trials. The completion of the preparation radio labeled ENT-103 was more difficult and time consuming than anticipated. As many steps in the development process are sequentially time-dependent, the delay in the preparation of the radio labeled ENT-103 has forced us to reschedule selected preclinical studies and our planned IND filing for ENT-103, which will postpone the commencement of our human clinical trials. Although the revised schedule will depend on the time slots available from our third party providers, we expect a four to six month delay in our previously projected timeline. To minimize the financial impact of this delay, we have developed a plan that includes reducing our expenditures to conserve our cash reserves in the formulation development of ENT-103," explained Thomas G. Tachovsky, PhD., Entropin's President and CEO.

During the first quarter of 2004, the Company completed a secondary stock offering. It was expected that the approximately $3.4 million net proceeds raised in the offering would provide sufficient capital to complete the Phase I clinical study with ENT-103. The recent delay in the preparation of radio labeled ENT-103 now necessitates an acceleration of Entropin's plan to raise additional capital. The Company intends to expedite discussions with our funding sources while it continues to explore strategic alternatives such as a merger or joint venture.

Entropin, Inc. is a pharmaceutical research and development company focused on the development of its proprietary compound, ENT-103, as a potent therapy for pain. Preclinical work shows that ENT-103, effectively blocks nerve impulse conduction, has potentially long-lasting properties to reduce and manage pain, and may also be effective in relieving both primary and secondary hyperalgesia (pain hypersensitivity) caused either by injury or incision.

Statements in this press release that are not strictly historical may be "forward-looking" statements, which involve risks and uncertainties. No assurances can be given, for example, that the Company will successfully raise additional capital, develop its current products, or any new products it may pursue, complete clinical trials, obtain regulatory approvals, or be able to manufacture or successfully commercialize such products. Actual results may differ materially from those described in this release due to risks and uncertainties that exist in the Company's operations, including, without limitation, the ability to successfully complete development and commercialization of products, including the cost, scope and results of preclinical and clinical testing, the ability to successfully complete product research and further development, including preclinical and clinical studies, the time, cost and uncertainty of obtaining regulatory approvals, the ability to obtain substantial additional funding, the ability to develop and commercialize products before competitors and other factors detailed from time to time in filings with the Securities and Exchange Commission including, without limitation, the Company's Annual Report on Form 10-KSB for the most recent fiscal year end and the Company's most recent Form 10-QSB. The Company undertakes no obligation to release publicly the results of any revision to these forward-looking statements to reflect events or circumstances arising after the date hereof.

For further information, please contact Thomas Tachovsky, Ph.D., President and CEO, or Patricia Kriss, CFO and VP, Finance & Administration, both of Entropin, Inc., +1-760-775-8333, info@Entropin.com.

SOURCE Entropin, Inc.